The innovative power of Belgium

"The decision to build the new European production facility in Belgium is a recognition of the unique local life sciences ecosystem, which is highly regarded within the global innovative life sciences environment. The development and production of transformative therapies such as CAR-T cell therapy require great innovative strength and strong collaboration. By choosing Belgium, we are building on the significant presence and expertise of Janssen in the field of science and production, as well as the strong local know-how, infrastructure and talent. The site is expected to be operational in 2023.  The arrival of the CAR-T production facility is a recognition of the strong Belgian Life Sciences ecosystem that is highly regarded as a world-class biopharma hub", said Sonja Willems, Managing Director Janssen Benelux

“The most important raw material in Flanders is our brains. That is why we are fully committed to technological innovation with our recovery plan. Biotech is one of our showpieces. That is why I am so pleased that Flanders will have the first cell therapy production site in Europe. This put our region on the map internationally”, said Minister-President of the Flemish Government Jan Jambon.